Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.53 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK3 | P49761 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636278 | 1.00 | ROCK2 (0.53) | ROCK2NOS1ROCK1MAPTMETAP2 | |
| Hydrochloric Acid SCHEMBL29957203 | 0.98 | ROCK2 (0.52) | ROCK2NOS1ROCK1MAPTMETAP2 | |
| SCHEMBL2241556 | 0.85 | NOS1 (0.53) | NOS1MAPTMETAP2KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL29952394 | 0.83 | NOS1 (0.52) | NOS1MAPTMETAP2KDM4EMEN1 | |
| SCHEMBL14935010 | 0.77 | ROCK2 (0.49) | ROCK2NOS1ROCK1MAPTMETAP2 | |
| SCHEMBL27159877 | 0.75 | ALDH1A1 (0.51) | KDM4EALDH1A1HPGDRAB9ATDP1 | |
| SCHEMBL8835 | 0.74 | ROCK1 (0.41) | ROCK2NOS1ROCK1MAPTMETAP2 | |
| SCHEMBL29520931 | 0.74 | ROCK2 (0.59) | ROCK2NOS1ROCK1MAPTMETAP2 | |
| SCHEMBL277777 | 0.74 | ROCK2 (0.59) | ROCK2NOS1ROCK1MAPTMETAP2 | |
| Hydrochloric Acid SCHEMBL27782875 | 0.72 | ROCK2 (0.57) | ROCK2NOS1ROCK1MAPTMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739675-A1 | INDOLE DERIVATIVES WITH FACTOR B INHIBITORY ACTIVITY | Sitala Bio Ltd (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | disclosed |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-07-03 | — | — | US | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| WO-2009126635-A1 | 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-2078003-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008054702-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | ROCK2 803/4885NOS1 398/4885ROCK1 643/4885 |
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | ROCK2 713/4885NOS1 3828/4885ROCK1 589/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | ROCK2 1699/4885NOS1 2521/4885ROCK1 1103/4885 |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | ROCK2 53/4885NOS1 2727/4885ROCK1 21/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | ROCK2 3267/4885NOS1 3441/4885ROCK1 3747/4885 |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | ROCK2 4367/4885NOS1 375/4885ROCK1 3548/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | ROCK2 3189/4885NOS1 3716/4885ROCK1 3228/4885 |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | ROCK2 2537/4885NOS1 1628/4885ROCK1 2457/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ROCK2 376/4885NOS1 3653/4885ROCK1 236/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | ROCK2 446/4885NOS1 2223/4885ROCK1 607/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | ROCK2 1739/4885NOS1 1398/4885ROCK1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.